In Stockhead: Race Oncology races ahead in FY24 with key milestones
In Stockhead: Race Oncology races ahead in FY24 with key milestones
Race Oncology is pleased to release the FY24 annual report. Key highlights include: Read the full report via this link....
Race featured in Stockhead’s Investor Guide: Health & Biotech FY25
Race featured in Stockhead’s Investor Guide: Health & Biotech FY25
Race is pleased to be featured in Stockhead’s Investor Guide this year. The Investor Guide showcases strong forces from the Australian health and biotech sector, offering deep insights to ASX investors. In this feature,...
Proactive: Race Oncology receives positive results from AML trial of Bisantrene
Proactive: Race Oncology receives positive results from AML trial of Bisantrene
Race CEO Dr Daniel Tillett speaks with Jonathan Jackson in the Proactive studio to discuss positive results from an investigator-sponsored Phase 1b/2 trial of RC110 bisantrene for acute myeloid leukaemia (AML). Read the article...
The Australian reports the successful conclusion of Race’s lead drug AML study
The Australian reports the successful conclusion of Race’s lead drug AML study
The Australian reports the conclusion of Race’s Phase 1b/2 investigator-sponsored trial of RC110 bisantrene in relapsed or refractory acute myeloid leukaemia patients, conducted at the Chaim Sheba Medical Centre in Israel and led by...
Race Executive Director on Disrupt Radio
Race Executive Director on Disrupt Radio
Race Oncology Executive Director Dr Peter Smith joined Disrupt Radio to discuss building biotech businesses in Australia, what to look out for when investing in biotech businesses, and why Race’s lead drug bisantrene is...
What’s In Store For 2024: Race Oncology
What’s In Store For 2024: Race Oncology
2024 Preview: Race Oncology (ASX:RAC) from Stockhead on Vimeo. Stockhead’s Ashtyn Hiron sits down with Race Oncology (ASX:RAC) CEO Daniel Tillett to close the books on 2023 and gain a sneak peek into what’s around the corner. The clinical stage...
